Related Experiment Video
Updated: Feb 22, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Small molecule targeting of PTPs in cancer
John S Lazo1, Kelley E McQueeney1, James C Burnett2
1Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, United States.
Abstract:
Protein tyrosine phosphatases (PTPs) undeniably have a central role in the development and progression of human cancers. Historically, however, PTPs have not been viewed as privileged drug targets, and progress on identifying potent, selective, and cell-active small molecule PTP inhibitors has suffered accordingly. This situation is rapidly changing, however, due to biochemical advances in the study of PTPs and recent small molecule screening campaigns, which have identified potent and mechanistically diverse lead structures. These compounds are facilitating the exploration of the fundamental cellular processes controlled by PTPs in cancers, and could form the inflection point for new therapeutic paradigms for the treatment of a range of cancers. Herein, we review recent advances in the discovery and biological annotation of cancer-relevant small molecule PTP inhibitors.
Insights
Protein tyrosine phosphatases (PTPs) are key in cancer. New small molecule inhibitors offer hope for novel cancer treatments by targeting these critical enzymes.
Area of Science:
- Biochemistry
- Oncology
- Medicinal Chemistry
Background:
- Protein tyrosine phosphatases (PTPs) play a crucial role in human cancer development and progression.
- Historically, PTPs have been underrepresented as drug targets, hindering the development of effective inhibitors.
Purpose of the Study:
- To review recent advancements in the discovery of small molecule inhibitors targeting cancer-relevant PTPs.
- To highlight the biological annotation and therapeutic potential of these novel compounds.
Main Methods:
- Biochemical studies of PTPs.
- Small molecule screening campaigns.
- Lead structure identification and characterization.
Main Results:
- Identification of potent and mechanistically diverse small molecule PTP inhibitors.
- These inhibitors facilitate the exploration of PTPs' cellular roles in cancer.
- Compounds show promise for new cancer therapeutic strategies.
Conclusions:
- Recent advances are transforming PTPs into viable drug targets for cancer therapy.
- Novel small molecule inhibitors represent a potential inflection point for treating various cancers.
More Related Videos
10:26Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions
Published on: December 20, 2017
08:13Spatiotemporal Subcellular Manipulation of the Microtubule Cytoskeleton in the Living Preimplantation Mouse Embryo using Photostatins
Published on: November 30, 2021
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase